287 related articles for article (PubMed ID: 34470661)
1. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes.
Barnes BM; Nelson L; Tighe A; Burghel GJ; Lin IH; Desai S; McGrail JC; Morgan RD; Taylor SS
Genome Med; 2021 Sep; 13(1):140. PubMed ID: 34470661
[TBL] [Abstract][Full Text] [Related]
2. Investigating the suitability of
McCabe A; Zaheed O; McDade SS; Dean K
Front Cell Dev Biol; 2023; 11():1104514. PubMed ID: 36861035
[TBL] [Abstract][Full Text] [Related]
3. Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures.
Winterhoff B; Hamidi H; Wang C; Kalli KR; Fridley BL; Dering J; Chen HW; Cliby WA; Wang HJ; Dowdy S; Gostout BS; Keeney GL; Goode EL; Konecny GE
Gynecol Oncol; 2016 Apr; 141(1):95-100. PubMed ID: 27016234
[TBL] [Abstract][Full Text] [Related]
4. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
[TBL] [Abstract][Full Text] [Related]
5. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.
Olbrecht S; Busschaert P; Qian J; Vanderstichele A; Loverix L; Van Gorp T; Van Nieuwenhuysen E; Han S; Van den Broeck A; Coosemans A; Van Rompuy AS; Lambrechts D; Vergote I
Genome Med; 2021 Jul; 13(1):111. PubMed ID: 34238352
[TBL] [Abstract][Full Text] [Related]
6. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).
Talhouk A; George J; Wang C; Budden T; Tan TZ; Chiu DS; Kommoss S; Leong HS; Chen S; Intermaggio MP; Gilks B; Nazeran TM; Volchek M; Elatre W; Bentley RC; Senz J; Lum A; Chow V; Sudderuddin H; Mackenzie R; Leong SCY; Liu G; Johnson D; Chen B; Group A; Alsop J; Banerjee SN; Behrens S; Bodelon C; Brand AH; Brinton L; Carney ME; Chiew YE; Cushing-Haugen KL; Cybulski C; Ennis D; Fereday S; Fortner RT; García-Donas J; Gentry-Maharaj A; Glasspool R; Goranova T; Greene CS; Haluska P; Harris HR; Hendley J; Hernandez BY; Herpel E; Jimenez-Linan M; Karpinskyj C; Kaufmann SH; Keeney GL; Kennedy CJ; Köbel M; Koziak JM; Larson MC; Lester J; Lewsley LA; Lissowska J; Lubiński J; Luk H; Macintyre G; Mahner S; McNeish IA; Menkiszak J; Nevins N; Osorio A; Oszurek O; Palacios J; Hinsley S; Pearce CL; Pike MC; Piskorz AM; Ray-Coquard I; Rhenius V; Rodriguez-Antona C; Sharma R; Sherman ME; De Silva D; Singh N; Sinn P; Slamon D; Song H; Steed H; Stronach EA; Thompson PJ; Tołoczko A; Trabert B; Traficante N; Tseng CC; Widschwendter M; Wilkens LR; Winham SJ; Winterhoff B; Beeghly-Fadiel A; Benitez J; Berchuck A; Brenton JD; Brown R; Chang-Claude J; Chenevix-Trench G; deFazio A; Fasching PA; García MJ; Gayther SA; Goodman MT; Gronwald J; Henderson MJ; Karlan BY; Kelemen LE; Menon U; Orsulic S; Pharoah PDP; Wentzensen N; Wu AH; Schildkraut JM; Rossing MA; Konecny GE; Huntsman DG; Huang RY; Goode EL; Ramus SJ; Doherty JA; Bowtell DD; Anglesio MS
Clin Cancer Res; 2020 Oct; 26(20):5411-5423. PubMed ID: 32554541
[TBL] [Abstract][Full Text] [Related]
8. Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.
Zhu S; Zhang C; Cao D; Bai J; Yu S; Chen J; Wang J; Ren T; Yang J; Yu M; Xiao X; Gong Y; Guan Y; Li P; Yue Y; Yin R; Wang Y; An R; Lou G; Yuan J; Zhang G; Xia X; Yang L; Xiang Y
Oncogene; 2022 May; 41(22):3093-3103. PubMed ID: 35468938
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer and the evolution of subtype classifications using transcriptional profiling†.
Cook DP; Vanderhyden BC
Biol Reprod; 2019 Sep; 101(3):645-658. PubMed ID: 31187121
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients.
Buttarelli M; Ciucci A; Palluzzi F; Raspaglio G; Marchetti C; Perrone E; Minucci A; Giacò L; Fagotti A; Scambia G; Gallo D
J Exp Clin Cancer Res; 2022 Feb; 41(1):50. PubMed ID: 35120576
[TBL] [Abstract][Full Text] [Related]
11. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.
Tudrej P; Olbryt M; Zembala-Nożyńska E; Kujawa KA; Cortez AJ; Fiszer-Kierzkowska A; Pigłowski W; Nikiel B; Głowala-Kosińska M; Bartkowska-Chrobok A; Smagur A; Fidyk W; Lisowska KM
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018258
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes.
Way GP; Rudd J; Wang C; Hamidi H; Fridley BL; Konecny GE; Goode EL; Greene CS; Doherty JA
G3 (Bethesda); 2016 Dec; 6(12):4097-4103. PubMed ID: 27729437
[TBL] [Abstract][Full Text] [Related]
13. Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma.
Sallinen H; Janhonen S; Pölönen P; Niskanen H; Liu OH; Kivelä A; Hartikainen JM; Anttila M; Heinäniemi M; Ylä-Herttuala S; Kaikkonen MU
BMC Cancer; 2019 Nov; 19(1):1121. PubMed ID: 31744494
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
15. Circular RNA profiling reveals circRNA1656 as a novel biomarker in high grade serous ovarian cancer.
Gao Y; Zhang C; Liu Y; Wang M
Biosci Trends; 2019 May; 13(2):204-211. PubMed ID: 31019161
[TBL] [Abstract][Full Text] [Related]
16. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
17. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
Tan TZ; Ye J; Yee CV; Lim D; Ngoi NYL; Tan DSP; Huang RY
EBioMedicine; 2019 Dec; 50():203-210. PubMed ID: 31761620
[TBL] [Abstract][Full Text] [Related]
18. Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Chen GM; Kannan L; Geistlinger L; Kofia V; Safikhani Z; Gendoo DMA; Parmigiani G; Birrer M; Haibe-Kains B; Waldron L
Clin Cancer Res; 2018 Oct; 24(20):5037-5047. PubMed ID: 30084834
[No Abstract] [Full Text] [Related]
19. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.
Martins FC; Couturier DL; Paterson A; Karnezis AN; Chow C; Nazeran TM; Odunsi A; Gentry-Maharaj A; Vrvilo A; Hein A; Talhouk A; Osorio A; Hartkopf AD; Brooks-Wilson A; DeFazio A; Fischer A; Hartmann A; Hernandez BY; McCauley BM; Karpinskyj C; de Sousa CB; Høgdall C; Tiezzi DG; Herpel E; Taran FA; Modugno F; Keeney G; Nelson G; Steed H; Song H; Luk H; Benitez J; Alsop J; Koziak JM; Lester J; Rothstein JH; de Andrade JM; Lundvall L; Paz-Ares L; Robles-Díaz L; Wilkens LR; Garcia MJ; Intermaggio MP; Alcaraz ML; Brett MA; Beckmann MW; Jimenez-Linan M; Anglesio M; Carney ME; Schneider M; Traficante N; Pejovic N; Singh N; Le N; Sinn P; Ghatage P; Erber R; Edwards R; Vierkant R; Ness RB; Leung S; Orsulic S; Brucker SY; Kaufmann SH; Fereday S; Gayther S; Winham SJ; Kommoss S; Pejovic T; Longacre TA; McGuire V; Rhenius V; Sieh W; Shvetsov YB; Whittemore AS; Staebler A; Karlan BY; Rodriguez-Antona C; Bowtell DD; Goode EL; Høgdall E; Candido Dos Reis FJ; Gronwald J; Chang-Claude J; Moysich KB; Kelemen LE; Cook LS; Goodman MT; Fasching PA; Crawford R; Deen S; Menon U; Huntsman DG; Köbel M; Ramus SJ; Pharoah PDP; Brenton JD
Br J Cancer; 2020 Sep; 123(5):793-802. PubMed ID: 32555365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
